Fludarabine therapy in patients with splenic lymphoma with villous lymphocytes: an update.
Lefrère
F
F
Lévy
V
V
François
S
S
Delarue
R
R
Ifrah
N
N
Tilly
H
H
Valensi
F
F
Troussard
X
X
Varet
B
B
Hermine
O
O
D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D004248:DNA (Cytosine-5-)-Methyltransferases / Q000037:antagonists & inhibitors; D006801:Humans; D008214:Lymphocytes / Q000187:drug effects / Q000473:pathology*; D008223:Lymphoma / Q000188:drug therapy* / Q000473:pathology; D008875:Middle Aged; D013156:Splenectomy; D013160:Splenic Neoplasms / Q000188:drug therapy* / Q000473:pathology; D014740:Vidarabine / Q000031:analogs & derivatives* / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D004248:DNA (Cytosine-5-)-Methyltransferases; D014740:Vidarabine; C024352:fludarabine